MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/20.09.24 | Delayed Börse Stuttgart 16:50:57 29/05/2024 BST | ||
| 0.048 EUR | -7.69% |
|
| Current month | +18.18% | ||
| 1 month | +18.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 0.048 | -7.69% |
| 28/05/24 | 0.052 | +8.33% |
| 27/05/24 | 0.048 | -2.04% |
| 24/05/24 | 0.049 | 0.00% |
| 23/05/24 | 0.049 | +2.08% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 04:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME5GG6 |
| ISIN | DE000ME5GG60 |
| Date issued | 15/12/2023 |
| Strike | 600 $ |
| Maturity | 20/09/2024 (114 Days) |
| Parity | 100 : 1 |
| Emission price | 0.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.101 € |
|---|---|
| Lowest since issue | 0.034 € |
| Spread | 0.01 € |
| Spread % | 17.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant
